CCCC Historical PE Ratio image   This CCCC PE ratio history page last updated 11/7/2022
CCCC Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/3/2022
9.90-0.65-2.60NA
Q2 2022
8/4/2022
11.70-0.56-2.24NA
Q1 2022
5/5/2022
8.80-0.65-2.60NA
Q4 2021
2/24/2022
22.78-0.31-1.24NA
Q3 2021
11/10/2021
44.73-0.51-2.04NA
Q2 2021
8/11/2021
35.91-0.51-2.04NA
Q1 2021
5/13/2021
34.06-0.49-1.96NA
Q4 2020
3/11/2021
41.48-3.45-13.80NA
Q3 2020
11/12/2020
26.51-17.55-70.20NA
CCCC PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/3/2022
9.90-0.65-2.17NA
Q2 2022
8/4/2022
11.70-0.56-2.03NA
Q1 2022
5/5/2022
8.80-0.65-1.98NA
Q4 2021
2/24/2022
22.78-0.31-1.82NA
Q3 2021
11/10/2021
44.73-0.51-4.96NA
Q2 2021
8/11/2021
35.91-0.51-22.00NA
Q1 2021
5/13/2021
34.06-0.49NANA
Q4 2020
3/11/2021
41.48-3.45NANA
Q3 2020
11/12/2020
26.51-17.55NANA
Quotes delayed 20 minutes

Email EnvelopeFree CCCC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
C4 Therapeutics (CCCC) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

CCEL PE Ratio History
CCRN PE Ratio History
CCXI PE Ratio History
CDAK PE Ratio History
CDMO PE Ratio History
CDNA PE Ratio History
CDRE PE Ratio History
CDTX PE Ratio History
CDXC PE Ratio History
CELC PE Ratio History
How should the CCCC historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like C4 Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this CCCC Historical PE Ratio page.

What is the average historical PE for CCCC based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The CCCC historical PE ratio using the annualized quarterly earnings method works out to NA.

What is the average historical PE for CCCC based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The CCCC historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the CCCC Historical PE Ratio information for C4 Therapeutics' stock. The average CCCC historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CCCC historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CCCC historical PE result, against the recent PE: when this page was posted on 11/4/2022, the most recent closing price for CCCC had been 8.91, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CCCC or any other given stock, valuation analysis for CCCC can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate C4 Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CCCC. Thanks for visiting, and the next time you need to research CCCC Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Funds Holding AMCN, SSBI Average Annual Return, BLV market cap history.

 

CCCC Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.